Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease
All patients will have chest x-ray and pregnancy test (if female) prior to infliximab
treatment.
There will be total 5 study visits. At each visit, body weight will be measured, abdominal
exam will be performed , 2 tablespoonful of blood will be drawn, stool will be collected, a
questionnaire will be completed.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Changes of IL-2 and Treg cell levels
To determine if the change of IL-2 and Treg cell levels can be used clinically as a predictive marker for differentiating Infliximab responders from nonresponders
1 year
No
Zili Zhange, MD, PhD
Principal Investigator
Oregon Health and Science University
United States: Institutional Review Board
6572
NCT01266785
December 2010
July 2012
Name | Location |
---|---|
Oregon Health & Science University | Portland, Oregon 97201 |